Puxitatug
Puxitatug (INT-016) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer[1][2].
Product Specifications
CAS Number
[2760250-47-1]
Product Name Alternative
INT-016
UNSPSC
12352203
Target
CD276/B7-H3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/puxitatug.html
Purity
99.00
Solubility
10 mM in DMSO
Smiles
[Puxitatug]
Molecular Weight
(145 kDa)
References & Citations
[1]Marchesi S, et al. Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment. NPJ Precis Oncol. 2025 Jul 2;9 (1) :219. |[2]Kundel Y, et al. Adjuvant chemotherapy and whole abdominal irradiation for gastric carcinoma. Tumori. 2008 Jul-Aug;94 (4) :469-73.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
